The SAB was enthusiastic about our candidate V4C232 as new treatment in cirrhotic refractory ascites* and confirmed there is no new other therapeutic option, so far. SAB agreed with the proposal of V4CURE to consider the refractory ascites definition previously used in clinical trial.
(*) Definition of diuretic-resistant refractory ascites
: ascites that cannot be mobilized or that reoccur quickly regardless of moderate salt restriction and maximum dose of diuretics (400 mg of spironolactone and 160 mg of furosemide, or equivalent)